No services found
No Products found
100ug
AntibodySystem
Recombinant Proteins
Recombinant EBV/HHV4 EBNA1/BKRF1 protein is a genetically engineered protein that is derived from the Epstein-Barr virus (EBV) and the human herpesvirus 4 (HHV4). This protein is a fusion of the EBNA1 and BKRF1 proteins, which are two important antigens of the EBV and HHV4 viruses, respectively. Recombinant EBV/HHV4 EBNA1/BKRF1 protein has been extensively studied and has shown promising potential in various applications, especially in the field of immunology.
Recombinant EBV/HHV4 EBNA1/BKRF1 protein is a fusion protein that is made up of two distinct domains: the EBNA1 domain and the BKRF1 domain. The EBNA1 domain is derived from the EBNA1 protein of the EBV virus, while the BKRF1 domain is derived from the BKRF1 protein of the HHV4 virus. The two domains are linked by a flexible linker sequence, which allows for proper folding and stability of the recombinant protein.
The EBNA1 domain is responsible for the DNA binding activity of the recombinant protein, while the BKRF1 domain is responsible for the immunomodulatory activity. The structure of the recombinant protein has been extensively studied using techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, which have revealed a compact and well-defined structure.
Recombinant EBV/HHV4 EBNA1/BKRF1 protein has been shown to have multiple activities, making it a versatile protein with potential applications in various fields. The EBNA1 domain of the recombinant protein has been shown to have strong DNA binding activity, which is essential for the replication and maintenance of the EBV virus. This activity also makes the recombinant protein a potential target for antiviral therapies.
The BKRF1 domain of the recombinant protein has been shown to have immunomodulatory activity, which can modulate the immune response in various ways. This activity has been shown to enhance the production of cytokines, such as interferon-gamma and interleukin-2, which are important for the activation of immune cells. The recombinant protein has also been shown to have anti-inflammatory activity, making it a potential therapeutic agent for inflammatory diseases.
Recombinant EBV/HHV4 EBNA1/BKRF1 protein has shown potential in various applications, especially in the field of immunology. One of the main applications of this protein is in the development of vaccines against EBV and HHV4 infections. The recombinant protein can be used as an antigen in vaccine formulations to induce a protective immune response against these viruses.
In addition, the immunomodulatory activity of the recombinant protein makes it a potential therapeutic agent for various diseases. It has been shown to have promising results in preclinical studies for the treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. The recombinant protein has also been studied for its potential in cancer immunotherapy, as it can enhance the immune response against cancer cells.
In conclusion, recombinant EBV/HHV4 EBNA1/BKRF1 protein is a genetically engineered protein with a well-defined structure and multiple activities. It has shown potential in various applications, especially in the field of immunology. Further research and development of this protein can lead to its use in the development of vaccines and therapeutic agents for various diseases.
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Related products
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.